Compartilhar
Informação da revista

Conteúdo especial sobre o coronavírus SARS-CoV-2 (COVID-19) em Hematology, Transfusion and Cell Therapy

INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Filip Callewaert, Hilde De Winter
10.1016/j.htct.2021.10.1047
Hematol Transfus Cell Ther. 2021;43 Supl 3:S46-7
Open access
IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
Hana Qasim
10.1016/j.htct.2021.10.1046
Hematol Transfus Cell Ther. 2021;43 Supl 3:S46
Open access
HEMATOLOGICAL FINDINGS IN COVID-19 AND INSIGHTS TO STEM CELL THERAPY
Ghada ELGohary
10.1016/j.htct.2021.10.1050
Hematol Transfus Cell Ther. 2021;43 Supl 3:S48
Open access
DOES BLOOD TYPE HAVE AN EFFECT ON THE COURSE OF COVID-19?
Fatma YILMAZ, Murat ALBAYRAK, Abdülkerim YILDIZ, Hacer Berna AFACAN ÖZTÜRK, Senem MARAL, Pınar AKYOL, Merih REİS ARAS, Buğra SAĞLAM, Mesut TIĞLIOĞLU
10.1016/j.htct.2021.10.1056
Hematol Transfus Cell Ther. 2021;43 Supl 3:S50
Open access
RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA AFTER MRNA COVID-19 VACCINE (PFIZER-BIONTECH)
Fatma YILMAZ, Murat ALBAYRAK, Merih REİS ARAS, Senem MARAL, Hacer Berna AFACAN ÖZTÜRK, Pınar TIĞLIOĞLU, Mesut TIĞLIOĞLU, Buğra SAĞLAM
10.1016/j.htct.2021.10.1057
Hematol Transfus Cell Ther. 2021;43 Supl 3:S50
Open access
A RARE ASSOCIATION IN A CASE WITH HEREDITARY SPHEROCYTOSIS: SPECTRIN BETA (SPTB) AND JAK-2 MUTATION
Fatma YILMAZ, Murat ALBAYRAK, Merih REİS ARAS, Senem MARAL, Hacer Berna AFACAN ÖZTÜRK, Pınar TIĞLIOĞLU, Mesut TIĞLIOĞLU, Buğra SAĞLAM
10.1016/j.htct.2021.10.1060
Hematol Transfus Cell Ther. 2021;43 Supl 3:S51
Open access
WHAT HAVE WE EXPERIENCED WITH COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISORDERS?
Simge ERDEM, Metban MASTANZADE, Mustafa Murat OZBALAK, Sevda SERT EKINCI, Dilek Ozden OZLUK, Tarık Onur TIRYAKI, Beyza OLUK, Ipek YONAL HINDILERDEN, Mustafa Nuri YENEREL, Meliha NALCACI, Tufan TUKEK, Sevgi KALAYOGLU BESISIK
10.1016/j.htct.2021.10.1063
Hematol Transfus Cell Ther. 2021;43 Supl 3:S52
Open access
How to COVID pandemic changed clinical practice
Medine Yılmaz
10.1016/j.htct.2021.11.007
Hematol Transfus Cell Ther. 2021;43 Supl 3:S69
Open access
PURPURA TROPOCITOPÊNICA TROMBÓTICA POSSIVELMENTE ASSOCIADA À VACINA CONTRA COVID-19
T Gavron, MAB Beleze, FC Trigo, LC Franco
10.1016/j.htct.2021.10.045
Hematol Transfus Cell Ther. 2021;43 Supl 1:S26-7
Open access
INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2
H Einsele, S Parekh, D Madduri, B Santomasso, JG Pérez-Larraya, NWV Donk, B Arnulf, M Mateos, KC Braganca, H Varsos, MJ Carrasco-Alfonso, M Akram, N Lendvai, CC Jackson, Y Olyslager, E Zudaire, C Li, D Geng, A Jakubowiak, A Cohen
10.1016/j.htct.2021.10.447
Hematol Transfus Cell Ther. 2021;43 Supl 1:S263-4
Open access
Idiomas
Hematology, Transfusion and Cell Therapy

Receba a nossa Newsletter